- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 01-12-2025: Press Release
01-12-2025 | 07:34 am
01-12-2025 | 07:34 am
Lupin received US FDA approval for its first biosimilar, Armlupeg™ (Pegfilgrastim-unne), for cancer patients. This unlocks a significant market, with the reference product's annual sales estimated at USD 129.5 Cr in the U.S.
No comments yet. Be the first to comment!